Fig. 2: Anti-SARS-CoV-2 RBD B cells after vaccination.

a, b, Graphs summarizing the number of Wuhan-Hu-1 RBD (WT)-specific memory B cells (a) and the number of antigen-specific memory B cells cross-reactive with both WT and K417N/E484K/N501Y mutant RBD (b) per 10 million B cells for n = 32 individuals after prime and 1.3 and 5 months after full vaccination. Samples without a prime value are shown in black. c, Pie charts showing the distribution of IgG antibody sequences obtained for memory B cells from three representative individuals after prime and 1.3 and 5 months after the boost. Additional pie charts can be found in Extended Data Fig. 3. The number inside the circle indicates the number of sequences analysed for the individual denoted above the circle, with Pfizer-BioNTech vaccine indicated by (P) and Moderna vaccine indicated by (M). Pie slice size is proportional to the number of clonally related sequences. The black outline and associated numbers indicate the percentage of clonally expanded sequences detected at each time point. Coloured slices indicate persisting clones (same IGHV and IGLV genes, with highly similar complementarity-determining region 3 sequences (CDR3s)) found at more than one time point within the same individual, grey slices indicate clones unique to the time point and white slices indicate repeating sequences isolated only once per time point. d, Number of nucleotide (nt) somatic hypermutations (SHM) in IGHV and IGLV genes combined (n = 2,050; Supplementary Table 4) in the antibodies illustrated in c and Extended Data Fig. 3, compared with the number of mutations obtained 1.3 months (ref. ³) and 6.2 months (ref. ⁷) after infection (grey). Horizontal bars and red numbers indicate the mean value at each time point. Samples without a prime value are shown in black. Statistical significance in a, b and d was determined by two-tailed Kruskal–Wallis test with subsequent Dunn’s multiple-comparisons test.